A new research paper titled 'ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells' has been published in Oncotarget.
ABT199/Venetoclax synergism with thiotepa in acute myeloid leukemia cells retrieved 25 March 2024 from https://medicalxpress.com/news/2024-03-abt199venetoclax-synergism-thiotepa-acute-myeloid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Mar 22, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study finds outcomes after stem cell transplant in elderly patients with AML have improved since 2000According to a study published in Clinical Cancer Research, among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.
Read more »
Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplantAmong patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.
Read more »
A new antibody capture method reveals G-quadruplex landscape and its regulationA new research paper was published in Oncotarget entitled, 'G-quadruplex landscape and its regulation revealed by a new antibody capture method.'
Read more »
Unveiling mitochondrial mysteries to conquering cancer therapy resistanceNational University of Singapore (NUS) scientists have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukemia (AML), a type of aggressive blood cancer. The results are expected to contribute towards the identification of effective drugs for treating relapsed patients.
Read more »
NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemiaScientists from the National University of Singapore (NUS) have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukaemia (AML), a type of aggressive blood cancer.
Read more »
CHOP study uncovers metabolic key to faster immune responseResearchers from Children's Hospital of Philadelphia identified a key metabolite in cells that helps direct immune responses and explains at a single cell level why immune cells that most efficiently recognize pathogens, vaccines, or diseased cells grow and divide faster than other cells.
Read more »